InSysBio announces the upcoming workshop on Heta at Quantitative Systems Pharmacology Conference (QSPC 2026). The worksop will be held at Golden Tulip & Tulip Inn Leiden Centre, Leiden, the Netherlands on April 7, 2026, 1 PM – 5 PM.
This workshop introduces an engineering-oriented approach to quantitative systems pharmacology (QSP) modeling using the Heta language and its associated tools. The session focuses on how structured, modular, and process-based model descriptions can improve transparency, reuse, and reproducibility compared to traditional monolithic ODE-based workflows. Participants will be introduced to the core concepts of the Heta language, including process-based model formulation, modularization, and alternative model representations, with an emphasis on how these ideas support scalable QSP workflows rather than on detailed syntax or implementation.
The workshop demonstrates how Heta models are used in practice: from model specification to translation into standard formats and execution with different simulation tools. The session includes guided demonstrations of model conversion using the Heta compiler, basic simulation workflows with HetaSimulator, and an overview of a typical Heta project structure. Short, optional hands-on segments are included for participants who wish to follow along, while others may simply observe the demonstrations. The workshop is intended as an accessible entry point for researchers interested in engineering-style QSP workflows and evaluating whether such an approach fits their existing modeling practice.
What You Will Learn
Who Should Attend
The workshop is free of charge.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | June 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
1.
02 Jun 2020 13:24
InSysBio to announce the launch of QSP model of COVID-19
The new open source project to be developed and updated Online
InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|
3
|
4
|
5
1.
05 Jun 2020 15:04
InSysBio to present IRT Navigator 3
InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.
|
6
|
7
|
|
8
1.
08 Jun 2020 15:30
InSysBio to perform the first step in development of COVID-19 QSP model
InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|
9
|
10
|
11
|
12
1.
12 Jun 2020 16:45
InSysBio to release the new version of Cytocon DB 1.1.6.4
We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.
|
13
|
14
|
|
15
|
16
|
17
1.
17 Jun 2020 15:48
InSysBio to welcome its new team member Dr. Neil Benson
InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development
(Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.
|
18
|
19
|
20
|
21
|
|
22
1.
22 Jun 2020 17:04
InSysBio team posters to be presented at AACR Virtual Annual Meeting II
AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website
|
23
|
24
|
25
|
26
|
27
|
28
|
|
29
|
30
1.
30 Jun 2020 15:45
InSysBio to present COVID-19 QSP model further development
InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
| |||||
Thank you for your message! We will get back to you shortly.
